Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Intellia Therapeutics Reveals Publication Of Interim Phase 1 Data For NTLA-2002 In Patients With Hereditary Angioedema In The New England Journal Of Medicine

Author: Benzinga Newsdesk | January 31, 2024 06:09pm
The company said data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose and that NTLA-2002 was well-tolerated at all dose levels.

Posted In: NTLA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist